TY - JOUR
T1 - Pathology, proteomics and the pathway to personalised medicine
AU - Jin, Ping
AU - Lan, Jiang
AU - Wang, Kui
AU - Baker, Mark S
AU - Huang, Canhua
AU - Nice, Edouard C.
PY - 2018/3/4
Y1 - 2018/3/4
N2 - Introduction: As we move from a discovery to a translational phase in proteomics, with a focus on developing validated clinical assays to assist personalized medicine, there is a growing need for strong bidirectional interactions with the clinical pathology community. Thus, while on one hand the proteomics community will provide candidate biomarkers to assist in diagnosis, prognosis, surveillance, identification of individualized patient medication, and development and validation of new assays for diagnostic use, on the other the pathology community will assist with specific tissue identification and selection (e.g. laser capture microdissection, tissue sections for MS imaging), biobanking, validation of emerging automated histopathology techniques, preparation and classification of relevant patient medical reports, and assisting with the optimization of experimental design for clinical trials. Areas covered: Here we discuss these topics with a particular emphasis on recent publications and relevant initiatives and outline some of the hurdles that still remain for personalized medicine. Expert commentary: It is clear that effective crosstalk between the proteomics and pathology communities will greatly accelerate crossover of candidate biomarkers to personalized medicine, which will have significant benefits not only for patient wellbeing, but also the global healthcare budget. However, analysis of the big data generated may become rate-limiting.
AB - Introduction: As we move from a discovery to a translational phase in proteomics, with a focus on developing validated clinical assays to assist personalized medicine, there is a growing need for strong bidirectional interactions with the clinical pathology community. Thus, while on one hand the proteomics community will provide candidate biomarkers to assist in diagnosis, prognosis, surveillance, identification of individualized patient medication, and development and validation of new assays for diagnostic use, on the other the pathology community will assist with specific tissue identification and selection (e.g. laser capture microdissection, tissue sections for MS imaging), biobanking, validation of emerging automated histopathology techniques, preparation and classification of relevant patient medical reports, and assisting with the optimization of experimental design for clinical trials. Areas covered: Here we discuss these topics with a particular emphasis on recent publications and relevant initiatives and outline some of the hurdles that still remain for personalized medicine. Expert commentary: It is clear that effective crosstalk between the proteomics and pathology communities will greatly accelerate crossover of candidate biomarkers to personalized medicine, which will have significant benefits not only for patient wellbeing, but also the global healthcare budget. However, analysis of the big data generated may become rate-limiting.
KW - big data
KW - Biobanking
KW - liquid biopsy
KW - mass spectrometry
KW - microarrays
KW - pathology
KW - personalized medicine
KW - proteomics
UR - http://www.scopus.com/inward/record.url?scp=85041482491&partnerID=8YFLogxK
U2 - 10.1080/14789450.2018.1425618
DO - 10.1080/14789450.2018.1425618
M3 - Review Article
C2 - 29310484
AN - SCOPUS:85041482491
SN - 1478-9450
VL - 15
SP - 231
EP - 243
JO - Expert Review of Proteomics
JF - Expert Review of Proteomics
IS - 3
ER -